Clinical Trials Logo

Diabetic Retinopathy clinical trials

View clinical trials related to Diabetic Retinopathy.

Filter by:

NCT ID: NCT05930561 Recruiting - Clinical trials for Diabetic Retinopathy

4D-150 in Patients With Diabetic Macular Edema

Start date: August 9, 2023
Phase: Phase 2
Study type: Interventional

Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).

NCT ID: NCT05902650 Recruiting - Clinical trials for Diabetic Retinopathy

Correlation of Biochemical Indexes and Retinal Hemodynamic in Patients With Different Degrees of Diabetic Retinopathy

Start date: January 1, 2021
Phase:
Study type: Observational

All OCTA data and biochemical indexes of diabetic patients were acquired. A prediction model of diabetic retinopathy was built, and the random forest method was used to identify sensitive indicators.

NCT ID: NCT05883072 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Exploring the Effectiveness of AI Generative Models for Diabetic Patients

Start date: January 5, 2023
Phase:
Study type: Observational

We plan to explore the usability of Generative AI-Chatbot for Diabetic Patient

NCT ID: NCT05836194 Recruiting - Diabetes Mellitus Clinical Trials

Evaluation of Diabetic Retinopathy Using Ultra-Widefield Fundus Images Compared With Two-Field Fundus Images

Start date: February 1, 2023
Phase:
Study type: Observational

This study aims to compare the accuracy of evaluating diabetic retinopathy using ultra-widefield fundus images versus two-field fundus images. The hypothesis is that screening and grading diabetic retinopathy based on ultra-widefield fundus images may yield higher accuracy compared to the use of two-field fundus images.

NCT ID: NCT05752045 Recruiting - Glaucoma Clinical Trials

OphtAI Diagnostic Performance Validation for Automated Screening of Eye Diseases

OPHTAI-EVAL
Start date: June 28, 2023
Phase: N/A
Study type: Interventional

Evolucare OphtAI is a medical device offering automated, artificial intelligence powered, screening capabilities for Diabetic Retinopathy, Diabetic Macular Edema, Glaucoma, ARM and AMD, whose performances will by tested through the OphtAI-EVAL.

NCT ID: NCT05746975 Recruiting - Clinical trials for Retinopathy, Diabetic

Diabetic Retinopathy Classification: ETDRS 7-fields vs Widefield Imaging (ClarusDR)

ClarusDR
Start date: April 3, 2023
Phase:
Study type: Observational

The goal of this observational study is to analyse and compare Diabetic Retinopathy severity level using 30º ETDRS 7-fields and Wide-field Imaging techniques using Clarus 500 (Carl Zeiss Meditech Inc., Dublin, USA) and Optos (Optos, Dunfermline, UK) in diabetic patients with mild to moderate diabetic retinopathy. The main questions it aims to answer are: 1. To compare the Clarus 500TM wide-field imaging technique with the ETDRS 7-fields method in the assessment of DR severity level using the ETDRS DRSS.2. To compare the two wide-field imaging techniques (Clarus 500TM vs OptosTM) in the assessment of DR severity level using the ETDRS DRSS.3. To evaluate the peripheral area imaged by the wide-field Clarus 500TM and OptosTM to characterize DR lesions distribution (predominantly observed within or outside the ETDRS 7-fields) and severity (according to the ETDRS standard photos).4. To determine the relevance and frequency of DR PPL, located outside the ETDRS 7-fields area, and to explore PPL occurrence in different DR severity levels. Participants will undergo a non-invasive ophthalmological examination, which includes BCVA, 7-fields CFP and UWF FP to assess ETDRS DRSS level.

NCT ID: NCT05704491 Recruiting - Diabetes Mellitus Clinical Trials

AI Screening for Diabetic Retinopathy

AimdR
Start date: January 30, 2023
Phase:
Study type: Observational

The increasing prevalence of diabetes mellitus represents a major health problem, especially since around 40% of diabetic patients develop diabetic retinopathy, which severely impairs vision and can lead to blindness. This development could be prevented by annual check-ups and timely referral for treatment. However, there are major differences in the quality of examinations and bottlenecks in examination appointments. A solution to the problem could be the use of artificial intelligence (AI), especially deep learning. Initial studies have shown that deep learning algorithms can be used successfully to detect diabetic retinopathy. However, it remains to be clarified whether the use of AI can achieve a sufficiently high level of accuracy in the detection of retinopathies. Therefore, in the present study, the positive predictive value (PPV), the negative predictive value (NPV), the sensitivity (SEN) and the specificity (SPEZ) of the AI algorithm 'MONA-DR-Model' in the detection of diabetic retinopathy should be measured. In addition, it is to be examined how well the classification into mild and severe retinopathy corresponds and how well this new examination method is accepted by the patients.

NCT ID: NCT05642793 Recruiting - Clinical trials for Proliferative Diabetic Retinopathy

Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

This is an unmasking randomized clinical trial. the main purpose of this study is to analyze whether posvitrectomy proactive use of conbercept can reduce the rate of postoperative complication in PDR patients.

NCT ID: NCT05631054 Recruiting - Clinical trials for Proliferative Diabetic Retinopathy

Establishment and Validation of a Risk Prediction Model for Long-term Low Vision After Vitrectomy in PDR Patients

Start date: November 10, 2022
Phase:
Study type: Observational

Diabetic retinopathy (DR) is the main cause of blindness among working-age adults in the world. Proliferative diabetic retinopathy (PDR) is the severe stage of DR, which is characterized by neovascularization of the retina. Vitreous hemorrhage and traction retinal detachment caused by PDR often require vitrectomy. The purpose of vitrectomy is to remove vitreous hemorrhage, peel off the preretinal proliferative membrane and help restore the retina. With the deepening of people's understanding of diabetes and the development and application of various hypoglycemic drugs, the life expectancy of patients with diabetes continues to prolong. Therefore, the goal of vitrectomy in patients with DR is not only to prevent blindness, but also to maintain good vision for a long time. The purpose of this study is to analyze the risk factors related to the occurrence of long-term low vision postoperatively and establish a risk prediction model, which can help patients adjust their psychological expectations reasonably and promote communication between doctors and patients.

NCT ID: NCT05615740 Recruiting - Clinical trials for Diabetic Retinopathy

Prevention of Onset and Transition to an Advanced Form of Diabetic Retinopathy in Children

Start date: May 2, 2022
Phase: N/A
Study type: Interventional

The primary goal of the project is to create a normative database from data collected from a healthy pediatric population. A secondary aim is to compare normative data with data from pediatric patients with pre-existing type 1 diabetes mellitus.